0001752026-18-000001.txt : 20180907 0001752026-18-000001.hdr.sgml : 20180907 20180907171320 ACCESSION NUMBER: 0001752026-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: 4a5 FILED AS OF DATE: 20180907 DATE AS OF CHANGE: 20180907 EFFECTIVENESS DATE: 20180907 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Linnaeus Therapeutics, Inc. CENTRAL INDEX KEY: 0001752026 IRS NUMBER: 474846130 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-320902 FILM NUMBER: 181060795 BUSINESS ADDRESS: STREET 1: 30 WASHINGTON AVENUE, SUITE F CITY: HADDONFIELD STATE: NJ ZIP: 08033 BUSINESS PHONE: 856-433-1500 MAIL ADDRESS: STREET 1: 30 WASHINGTON AVENUE, SUITE F CITY: HADDONFIELD STATE: NJ ZIP: 08033 D 1 primary_doc.xml X0708 D LIVE 0001752026 Linnaeus Therapeutics, Inc. 30 Washington Avenue, Suite F Haddonfield NJ NEW JERSEY 08033 (856) 433-1500 DELAWARE None None Corporation true 2015 Patrick T. Mooney 30 Washington Avenue, Suite F Haddonfield NJ NEW JERSEY 08033 Executive Officer Director Michael D. Poisel 30 Washington Avenue, Suite F Haddonfield NJ NEW JERSEY 08033 Director Christopher Natale 30 Washington Avenue, Suite F Haddonfield NJ NEW JERSEY 08033 Executive Officer Nicholas Iatropoulos 30 Washington Avenue, Suite F Haddonfield NJ NEW JERSEY 08033 Director Biotechnology Decline to Disclose 06b 4a5 false 2018-08-27 false true false 0 Indefinite 2160000 Indefinite A second tranche of $2,160,000 will be sold within the next 9 months if the issuer achieves certain milestone events. false 4 0 0 100000 true Approximately $100,000 of the proceeds of this offering may be used to repay the principal of a promissory note made to the issuer by the issuer's CEO. The decision to repay the principal will be at the discretion of the issuer's board of directors. false Linnaeus Therapeutics, Inc. Adam Chelminiak Adam Chelminiak Attorney-in-fact 2018-09-07